Aspira Women's Health Logo
US04537Y1091
A2P6V3
AWH

Aspira Women's Health

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 2,84 € (+3992,22%). La mediana è 2,84 € (+3992,22%).

Acquista
  3
Mantieni
  2
Vendi
  0

  • Aspira Women’s Health: shareholders approve all annual meeting proposals

    At Aspira Women’s Health’s annual general meeting, all four proposals put to a vote were approved. Six directors were elected for one year, executive compensation was approved on an advisory basis, and the stock incentive plan was increased by 5,000,000 to 9,532,818 shares. Shareholders also ratified BDO USA, P.C. as the independent auditor; the meeting was 62.40% represented. The stock has returned 310% over the past year, but the company still faces profitability challenges on $8.9 million in revenue for the last twelve months. » Altro su de.investing.com


  • Aspira Women’s Health closes subordinated, secured loan of USD 1.05 million

    Aspira Women’s Health has entered into a subordinated, secured loan agreement with Agile Lending for USD 1.05 million, evidenced by a Subordinated Secured Promissory Note due August 26, 2026. If repaid on schedule, total interest costs will amount to USD 441,000; the loan is expressly subordinated to senior obligations. The company granted additional security interests in substantially all of its tangible assets and may use the proceeds for general corporate purposes; the agreement contains customary covenants, and lenders may enforce the security on covenant breaches. » Altro su de.investing.com


  • Aspira Women’s Health names Brian Hungerford chief financial officer

    Aspira Women’s Health has named Brian Hungerford chief financial officer and head of accounting, effective Tuesday; he succeeds Julie Carrillo. Hungerford will receive an annual salary of $300,000, a performance-based cash bonus of up to 35%, and stock options on 100,000 shares with staggered vesting beginning September 2, 2026. The contract includes termination and severance provisions for dismissal without cause and special provisions in the event of a change in control. The company also appointed Jane Pine Wood to the board of directors to strengthen the leadership team. » Altro su de.investing.com

Nel 2009, Aspira Women's Health ha già distribuito 0,13 € di dividendi. L'ultimo pagamento è avvenuto a giugno 2009.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Aspira Women's Health ha registrato ricavi pari a 1,79 Mln € e un utile netto di -2,12 Mln €
(EUR) giu 2026
YoY
Ricavi 1,79 Mln 12,10%
Utile lordo 990,99K 23,86%
Utile netto -2,12 Mln 6,25%
EBITDA -1,61 Mln 28,27%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
2,12 Mln €
Numero di azioni
29,98 Mln
Massimo/minimo a 52 settimane
3,12 € - 0,0689 €
Dividendi No
Beta
2,01
Rapporto P/E
-0,34
Rapporto PEG
0,00
Rapporto P/B
-0,50
Rapporto P/S
0,29

Profilo aziendale

Aspira Women's Health Inc. entwickelt und vertreibt zusammen mit seinen Tochtergesellschaften diagnostische Tests für gynäkologische Erkrankungen in den Vereinigten Staaten. Das Unternehmen bietet OVA1, OVERA und OVA1plus an, um das Risiko einer bösartigen Erkrankung der Eierstöcke bei Frauen mit Adnexen zu erkennen. Außerdem bietet es ASPiRA GenetiX an, einen genetischen Test für das Risiko von gynäkologischem Krebs. Darüber hinaus betreibt das Unternehmen Aspira Synergy, eine Testplattform und einen Cloud-Service für den dezentralen Zugang zu Protein-Biomarkern und Gentests für die Vererbung, und besitzt und betreibt ASPiRA LABS, ein Labor, das sich auf die Anwendung von Biomarker-basierten Technologien spezialisiert hat, um kritische Bedürfnisse bei der Behandlung von gynäkologischen Krebsarten und Krankheiten zu erfüllen. Zu den Produkten in der Pipeline des Unternehmens gehören OVAWatch, EndoCheck und OVAInherit. Das Unternehmen beliefert Ärzte, Laboratorien in Arztpraxen sowie nationale und regionale Laboratorien. Es hat eine Forschungskooperation mit Baylor Genetics, eine Vereinbarung mit dem Harvard Dana-Farber Cancer Institute, dem Brigham and Women's Hospital und der Medizinischen Universität Lodz zur Evaluierung der microRNA-Technologie in Kombination mit Aspira-Technologien für die Entwicklung eines Früherkennungstests für Eierstockkrebs sowie eine strategische Allianz mit Quest Diagnostics, Incorporated. Das Unternehmen war früher als Vermillion, Inc. bekannt und änderte im Juni 2020 seinen Namen in Aspira Women's Health Inc. Aspira Women's Health Inc. wurde 1993 gegründet und hat seinen Hauptsitz in Austin, Texas.

Nome
Aspira Women's Health
CEO
Nicolette Possemato
Sede centrale Austin, tx
Stati Uniti
Sito web
Settore
Sanità
Industria
Attrezzature e forniture sanitarie
Quotazione in borsa
02/10/2000
Dipendenti 66

Simboli di borsa

Borsa Simbolo
NASDAQ
AWH
Frankfurt
CUL1.F
München
CUL1.MU
🍪

Parqet  usa i cookie. Scopri di più